BioSyent Inc. (CVE:RX – Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$13.60 and traded as low as C$13.56. BioSyent shares last traded at C$13.76, with a volume of 1,940 shares traded.
BioSyent Stock Up 1.4%
The company has a debt-to-equity ratio of 11.66, a quick ratio of 6.91 and a current ratio of 1.89. The company has a market cap of C$159.56 million, a price-to-earnings ratio of 17.79 and a beta of 1.02. The stock’s fifty day moving average is C$14.71 and its two-hundred day moving average is C$13.63.
About BioSyent
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Featured Articles
- Five stocks we like better than BioSyent
- Modine’s $4B AI Coup Freezes Out the Competition
- What Investors Need to Know About TSMC’s Hefty 17% Dividend Increase
- The SpaceX IPO Frenzy Is Creating 2 Very Different Bets
- AI Can’t Reach the Real World Without These 3 Stocks
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
